Fractyl Health (GUTS) Research & Development (2023 - 2026)
Fractyl Health's (GUTS) quarterly Research & Development came in at $15.6 million in Q1 2026, down 19.74% YoY from $19.4 million in Q1 2025, and down 5.43% on a QoQ basis from $16.5 million in Q4 2025.
Fractyl Health (GUTS) Research & Development (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Research & Development data on file, last reported at $15.6 million in Q1 2026.
- Quarterly Research & Development fell 19.74% year-over-year to $15.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70.7 million (down 6.34% YoY) and the FY2025 annual result came in at $74.5 million, up 5.77% from the prior year.
- Research & Development retreated to $15.6 million in Q1 2026, from $16.5 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $21.2 million in Q2 2025 to a low of $9.1 million in Q2 2023.
- A 4-year average of $15.3 million and a median of $16.5 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development jumped 102.56% — and 2026, when it retreated 19.74%.
- Tracing GUTS's Research & Development over 4 years: stood at $10.2 million in 2023, then soared by 99.5% to $20.3 million in 2024, then fell by 18.68% to $16.5 million in 2025, then retreated by 5.43% to $15.6 million in 2026.
- The last three Research & Development figures came in at $15.6 million (Q1 2026), $16.5 million (Q4 2025), and $17.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Fractyl Health | 109.12 Mn | 109.12 Mn | - | 13.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.81 Mn |
| Mar 31, 2026 | 15.60 Mn |
| Dec 31, 2025 | 16.49 Mn |
| Sep 30, 2025 | 17.46 Mn |
| Jun 30, 2025 | 21.15 Mn |
| Mar 31, 2025 | 19.44 Mn |
| Dec 31, 2024 | 20.28 Mn |
| Sep 30, 2024 | 19.00 Mn |
| Jun 30, 2024 | 16.76 Mn |
| Mar 31, 2024 | 14.42 Mn |
| Dec 31, 2023 | 10.17 Mn |
| Sep 30, 2023 | 9.38 Mn |
| Jun 30, 2023 | 9.14 Mn |
| Mar 31, 2023 | 9.35 Mn |